General Dermatology

Chronic itching can reflect systemic disease, highlighting the importance of comprehensive assessment.

Kim explores the significance of inflammation in dermatology, revealing its connections to various diseases and the importance of focused research.

Shannon Trotter, DO, and Renata Block, DMSc, MMS, PA-C, discuss social media's impact on dermatology, highlighting trends, misinformation, and the need for clinician engagement.

Lindsay Ackerman, MD, FAAD, shares practical insights on managing vitiligo with topical ruxolitinib, addressing patient expectations, safety, and evolving research gaps.

FDA updates labeling for menopausal hormone therapy, removing broad boxed warnings and adding guidance for younger symptomatic patients.

Hussein Abbas, MD, PhD, discusses systemic mastocytosis challenges and the essential collaboration needed for optimal patient care.

Amanda Mixon, PA-C, highlights critical cutaneous signs of connective tissue diseases at SDPA 2025, enhancing early diagnosis and treatment strategies.

Explore the latest FDA approvals in dermatology, including treatments for eczema and psoriasis, and gain insights on chronic spontaneous urticaria.

From acne to psoriasis, nutrition influences disease severity, treatment response, and patient quality of life.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about upadacitinib for vitiligo, the commercial release of roflumilast for pediatric AD, a recap of the top pearls at Fall Clinical 2025, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Christopher Bunick, MD, PhD, emphasizes how dermatologists can improve outcomes through vigilant skin exams and collaborative care with oncology teams.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

CURE spoke with experts about possible dermatologic adverse effects faced by patients with breast cancer.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Updated FDA policies eliminate many comparative efficacy trials, reducing biosimilar development time and cost by relying more on analytical testing.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Learn more about the in-depth topics covered in the October 2025 print issue of Dermatology Times.

Explore the intricate relationship between rheumatologic dermatology and breast cancer, highlighting diagnostic challenges and treatment insights for dermatologists.

Explore a personal journey of resilience and proactive choices in the fight against breast cancer during Breast Cancer Awareness Month.

Recent FDA approvals for topical roflumilast and ruxolitinib down to age 2 mark major milestones in managing pediatric AD, according to Peter Lio, MD.

Del Rosso recounts the meeting’s evolution and its consistent mission to bridge science and practice.

Click through this slideshow to see what faces familiar to Dermatology Times will be on the speaker stand at Fall Clinical this week.